Replies to post #164342 on Amarin Corp Plc (AMRN)

[ziploc_1]

Amarin is faced with a conundrum....Vascepa needs to be made available soon in Europe:.....The choices are:
1. utilizing an outlay of considerable funds by Amarin(funds which Amarin does not have at this time)
2.an EU partner
3.a BP BO of Amarin

IMO if the price is high enough, Amarin would accept a BO

However a BP will not offer a high enough bid until two things happen
1. more proof of Vascepa dominance in the U.S. market
2. FDA approval of Vascepa for CVD

Therefore I believe that Amarin will be "forced" to take on a European partner and gamble that Vasceps will drive enough revenue to GIA everywhere(i.e. become a BP itself)......when you think about it, this is less of a gamble than Amarin took in 2013 when it chose to stay with R-IT until completion.